1
|
Hervé PL, Dioszeghy V, Matthews K, Bee KJ, Campbell DE, Sampson HA. Recent advances in epicutaneous immunotherapy and potential applications in food allergy. FRONTIERS IN ALLERGY 2023; 4:1290003. [PMID: 37965375 PMCID: PMC10641725 DOI: 10.3389/falgy.2023.1290003] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 10/06/2023] [Indexed: 11/16/2023] Open
Abstract
Given the potent immunological properties of the skin, epicutaneous immunotherapy (EPIT) emerges as a promising treatment approach for inducing immune tolerance, particularly for food allergies. Targeting the highly immunocompetent, non-vascularized epidermis allows for the application of microgram amounts of allergen while significantly reducing the risk of allergen passage into the bloodstream, thus limiting systemic allergen exposure and distribution. This makes EPIT highly suitable for the treatment of potentially life-threatening allergies such as food allergies. Multiple approaches to EPIT are currently under investigation for the treatment of food allergy, and these include the use of allergen-coated microneedles, application of allergen on the skin pretreated by tape stripping, abrasion or laser-mediated microperforation, or the application of allergen on the intact skin using an occlusive epicutaneous system. To date, the most clinically advanced approach to EPIT is the Viaskin technology platform. Viaskin is an occlusive epicutaneous system (patch) containing dried native allergen extracts, without adjuvants, which relies on frequent application for the progressive passage of small amounts of allergen to the epidermis through occlusion of the intact skin. Numerous preclinical studies of Viaskin have demonstrated that this particular approach to EPIT can induce potent and long-lasting T-regulatory cells with broad homing capabilities, which can exert their suppressive effects in multiple organs and ameliorate immune responses from different routes of allergen exposure. Clinical trials of the Viaskin patch have studied the efficacy and safety for the treatment of life-threatening allergies in younger patients, at an age when allergic diseases start to occur. Moreover, this treatment approach is designed to provide a non-invasive therapy with no restrictions on daily activities. Taken together, the preclinical and clinical data on the use of EPIT support the continued investigation of this therapeutic approach to provide improved treatment options for patients with allergic disorders in the near future.
Collapse
Affiliation(s)
| | | | | | | | - Dianne E. Campbell
- DBV Technologies, Montrouge, France
- Department of Allergy and Immunology, University of Sydney, Sydney, NSW, Australia
| | - Hugh A. Sampson
- Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| |
Collapse
|
2
|
Malek-Khatabi A, Tabandeh Z, Nouri A, Mozayan E, Sartorius R, Rahimi S, Jamaledin R. Long-Term Vaccine Delivery and Immunological Responses Using Biodegradable Polymer-Based Carriers. ACS APPLIED BIO MATERIALS 2022; 5:5015-5040. [PMID: 36214209 DOI: 10.1021/acsabm.2c00638] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Biodegradable polymers are largely employed in the biomedical field, ranging from tissue regeneration to drug/vaccine delivery. The biodegradable polymers are highly biocompatible and possess negligible toxicity. In addition, biomaterial-based vaccines possess adjuvant properties, thereby enhancing immune responses. This Review introduces the use of different biodegradable polymers and their degradation mechanism. Different kinds of vaccines, as well as the interaction between the carriers with the immune system, then are highlighted. Natural and synthetic biodegradable micro-/nanoplatforms, hydrogels, and scaffolds for local or targeted and controlled vaccine release are subsequently discussed.
Collapse
Affiliation(s)
- Atefeh Malek-Khatabi
- Department of Pharmaceutical Biomaterials, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran
| | - Zahra Tabandeh
- Department of Physical Chemistry, Faculty of Chemistry, University of Kashan, Kashan 8731753153, Iran
| | - Akram Nouri
- School of Chemistry, College of Science, University of Tehran, Tehran 141556455, Iran
| | - Elaheh Mozayan
- Department of Cell and Molecular Biology, University of Kashan, Kashan 8731753153, Iran
| | | | - Shahnaz Rahimi
- School of Chemistry, College of Science, University of Tehran, Tehran 141556455, Iran
| | - Rezvan Jamaledin
- Department of Chemical, Materials & Industrial Production Engineering, University of Naples Federico II, Naples 80125, Italy
| |
Collapse
|
3
|
Kitahata K, Matsuo K, Sato M, Susami Y, Hara Y, Morikawa T, Oiso N, Kawada A, Otsuka A, Nakayama T. Anti-allergic effect of ascorbic acid derivative DDH-1 in a mouse model of atopic dermatitis. Exp Dermatol 2022; 31:1234-1242. [PMID: 35441724 DOI: 10.1111/exd.14578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 03/24/2022] [Accepted: 04/17/2022] [Indexed: 11/28/2022]
Abstract
Atopic dermatitis (AD) is the most common inflammatory skin disease, which is characterized by excessive Th2 immune responses. In AD patients, the expression of the chemokines CCL17 and CCL22 is increased in skin lesions, leading to the infiltration of Th2 cells. In addition, typical pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, have also been shown to be associated with the pathogenesis of AD. Recently, DDH-1, an ascorbic acid derivative, has been synthesized and demonstrated to have a more stabilized structure and better skin penetrability. Furthermore, DDH-1 has been shown to suppress pro-inflammatory cytokine expression in vitro and in vivo. Therefore, using an AD mouse model, we evaluated the effect of DDH-1 to reduce allergic skin inflammation. We found that cutaneous administration of DDH-1 significantly reduced the expression levels of TNF-α, IL-1β, and IL-6 in the skin lesions of AD-like mice. Additionally, DDH-1 administration also significantly reduced the expression levels of CCL17 and CCL22, resulting in decreased skin infiltration of Th2 cells. Consequently, DDH-1 reduced ear and epidermal thickness, the serum IgE levels, and the number of infiltrating inflammatory cells and mast cells into the AD-like skin lesions. Combination treatment with DDH-1 and corticosteroid more efficiently improved the skin lesions compared to corticosteroid alone. Collectively, our results suggest that DDH-1 has an anti-allergic effect in an AD mouse model by reducing not only the pro-inflammatory cytokine expression but also the Th2-associated chemokine expression. Thus, DDH-1 may be beneficial for AD treatment and prevention as a monotherapy or in combination with corticosteroids.
Collapse
Affiliation(s)
- Kosuke Kitahata
- Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Higashi-Osaka, Kowakae 3-4-1, Osaka, 577-8502, Japan
| | - Kazuhiko Matsuo
- Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Higashi-Osaka, Kowakae 3-4-1, Osaka, 577-8502, Japan
| | - Masako Sato
- Department of Dermatology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama, Osaka, Japan
| | - Yoko Susami
- Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Higashi-Osaka, Kowakae 3-4-1, Osaka, 577-8502, Japan
| | - Yuta Hara
- Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Higashi-Osaka, Kowakae 3-4-1, Osaka, 577-8502, Japan
| | - Toshio Morikawa
- Department of Pharmaceutical Food Sciences, Pharmaceutical Research and Technology Institute, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan
| | - Naoki Oiso
- Department of Dermatology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama, Osaka, Japan
| | - Akira Kawada
- Department of Dermatology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama, Osaka, Japan
| | - Atsushi Otsuka
- Department of Dermatology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama, Osaka, Japan
| | - Takashi Nakayama
- Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Higashi-Osaka, Kowakae 3-4-1, Osaka, 577-8502, Japan
| |
Collapse
|
4
|
Chansoria P, Etter EL, Nguyen J. Regenerating dynamic organs using biomimetic patches. Trends Biotechnol 2022; 40:338-353. [PMID: 34412924 PMCID: PMC8831394 DOI: 10.1016/j.tibtech.2021.07.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 06/29/2021] [Accepted: 07/06/2021] [Indexed: 12/14/2022]
Abstract
The regeneration of dynamic organs remains challenging because they are intrinsically anisotropic and undergo large volumetric deformation during normal or pathological function. This hampers the durability and applicability of regenerative medicine approaches. To address the challenges of organ dynamics, a new class of patches have emerged with anisotropic and auxetic properties that mimic native tissue biomechanics and accommodate volumetric deformation. Here, we outline the critical design, materials, and processing considerations for achieving optimal patch biomechanics according to target pathology and summarize recent advances in biomimetic patches for dynamic organ regeneration. Furthermore, we discuss the challenges and opportunities which, if overcome, would open up new applications in organ regeneration and expedite the clinical translation of patch-based therapeutics.
Collapse
Affiliation(s)
| | | | - Juliane Nguyen
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
| |
Collapse
|
5
|
Liu G, Liu M, Wang J, Mou Y, Che H. The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy. Front Immunol 2021; 12:660974. [PMID: 34305893 PMCID: PMC8297384 DOI: 10.3389/fimmu.2021.660974] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Accepted: 06/28/2021] [Indexed: 12/13/2022] Open
Abstract
In recent decades, a rapid increase in the prevalence of food allergies has led to extensive research on novel treatment strategies and their mechanisms. Mouse models have provided preliminary insights into the mechanism of epicutaneous immunotherapy (EPIT)-induced immune tolerance. In EPIT, antigen applied on the skin surface can be captured, processed, and presented in the lymph nodes (LNs) by Antigen-presenting cells (APCs). In the LNs, induction of regulatory T cells (Treg cells) requires both direct contact during antigen presentation and indirect mechanisms such as cytokines. Foxp3+CD62L+ Treg cells can exhibit the characteristics of hypomethylation of Foxp3 TSDR and Foxp3-LAP+ Treg cells, which increase the expression of surface tissue-specific homing molecules to exert further sustained systemic immune tolerance. Studies have shown that EPIT is a potential treatment for food allergies and can effectively induce immune tolerance, but its mechanism needs further exploration. Here, we review Treg cells' role in immune tolerance induced by EPIT and provide a theoretical basis for future research directions, such as the mechanism of EPIT and the development of more effective EPIT treatments.
Collapse
Affiliation(s)
- Guirong Liu
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
| | - Manman Liu
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
| | - Junjuan Wang
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
| | - Yao Mou
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
| | - Huilian Che
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
| |
Collapse
|
6
|
Okada N. [Development of an Immune Regulation Technology Targeting the Skin and Promotion of the Practical Applications of Transcutaneous Vaccination/Immunotherapy]. YAKUGAKU ZASSHI 2020; 139:1129-1137. [PMID: 31474627 DOI: 10.1248/yakushi.19-00090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In the premise of vaccination and allergen-specific immunotherapy, transcutaneous formulations have an advantage over conventional subcutaneous injections in terms of convenience, simplicity of delivery, and painless administration into the skin. Additionally, since transcutaneous formulations can be rendered cold-chain free, they do not require expert handling during transportation, storage, and stockpiling, which enables reductions in costs and distribution to distant areas. Furthermore, transcutaneous formulations are effective for improving adherence in children with phobias toward injection needles and may help in persuading them to perform self-vaccination and home immunotherapy against allergies in the future. We have been promoting the development of innovative "patch-type formulations for vaccination and immunotherapy" which regard skin as an immune organ and utilize our original transcutaneous administration devices (hydrophilic gel patch and microneedle patch) for their delivery. We have confirmed the safety and efficacy of transcutaneous formulations not only in demonstration experiments using animals but also in physician-initiated clinical studies. Additionally, in order to elucidate the mechanism for the induction of immune responses by transcutaneous formulations, we analyzed the immunological events occurring in the skin and regional lymph nodes which accompanied the application of transcutaneous administration devices or the delivery of antigens (vaccines and allergens) to the skin surface layer. This review presents our results from basic to clinical research on the development of transcutaneous formulations for vaccines and allergen-specific immunotherapy.
Collapse
Affiliation(s)
- Naoki Okada
- Graduate School of Pharmaceutical Sciences, Osaka University
| |
Collapse
|
7
|
Ito S, Hirobe S, Kuwabara Y, Nagao M, Saito M, Quan YS, Kamiyama F, Fujisawa T, Okada N. Immunogenicity of Milk Protein-Containing Hydrophilic Gel Patch for Epicutaneous Immunotherapy for Milk Allergy. Pharm Res 2020; 37:35. [PMID: 31950282 DOI: 10.1007/s11095-019-2728-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 10/21/2019] [Indexed: 02/06/2023]
Abstract
PURPOSE Epicutaneous immunotherapy (EPIT) involving the skin's immune system is easy to use, painless and has a low risk of systemic side effects; it can be applied to food allergies that have a high morbidity rate in children. In this study, we evaluated the safety and efficacy of hydrophilic gel patch (HG) for EPIT. METHODS Milk protein concentrate (MPC)-containing HG was applied to the skin that maintained a barrier function or formed puncture holes with microneedle, and MPC-specific antibodies were measured. The clinical study was conducted involving patients with severe milk allergy. RESULTS No specific immune response was induced when immunizing to intact skin, and antibody production was observed by forming puncture holes. It was suggested that MPC contained in HG has immunogenicity and a very small amount of MPC was delivered to intact skin. In the clinical study, the symptom induction threshold increased in four of eight subjects, allowing them to consume milk and switch to oral immunotherapy. Although local skin reactions and temporary elevation of specific IgE antibodies were observed, no systemic side effects appeared throughout the study. CONCLUSIONS EPIT using HG is a safe method to enable oral administration even in patients with severe milk allergies.
Collapse
Affiliation(s)
- Sayami Ito
- Project for Vaccine and Immune Regulation, Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Sachiko Hirobe
- Advanced Research of Medical and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.,Project of Clinical Pharmacology and Therapeutics, Center for Advanced Education and Research in Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yu Kuwabara
- Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan
| | - Mizuho Nagao
- Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan
| | - Mio Saito
- CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan
| | - Ying-Shu Quan
- CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan
| | - Fumio Kamiyama
- CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan
| | - Takao Fujisawa
- Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan
| | - Naoki Okada
- Project for Vaccine and Immune Regulation, Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. .,Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
8
|
Kozaka S, Tahara Y, Wakabayashi R, Nakata T, Ueda T, Kamiya N, Goto M. Transcutaneous Cancer Vaccine Using a Reverse Micellar Antigen Carrier. Mol Pharm 2019; 17:645-655. [PMID: 31833775 DOI: 10.1021/acs.molpharmaceut.9b01104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Skin dendritic cells (DCs) such as Langerhans cells and dermal dendritic cells have a pivotal role in inducing antigen-specific immunity; therefore, transcutaneous cancer vaccines are a promising strategy to prophylactically prevent the onset of a variety of diseases, including cancers. The largest obstacle to delivering antigen to these skin DC subsets is the barrier function of the stratum corneum. Although reverse micellar carriers are commonly used to enhance skin permeability to hydrophilic drugs, the transcutaneous delivery of antigen, proteins, or peptides has not been achieved to date because of the large molecular weight of drugs. To achieve effective antigen delivery to skin DCs, we developed a novel strategy using a surfactant as a skin permeation enhancer in a reverse micellar carrier. In this study, glyceryl monooleate (MO) was chosen as a skin permeation enhancer, and the MO-based reverse micellar carrier enabled the successful delivery of antigen to Langerhans cells and dermal dendritic cells. Moreover, transcutaneous vaccination with the MO-based reverse micellar carrier significantly inhibited tumor growth, indicating that it is a promising vaccine platform against tumors.
Collapse
Affiliation(s)
| | | | | | - Takahiro Nakata
- Kobayashi Pharmaceutical Co., Ltd. , 1-30-3 Toyokawa , Ibaraki , Osaka 567-0057 , Japan
| | - Taro Ueda
- Kobayashi Pharmaceutical Co., Ltd. , 1-30-3 Toyokawa , Ibaraki , Osaka 567-0057 , Japan
| | | | | |
Collapse
|
9
|
Matsuo K, Hatanaka S, Kimura Y, Hara Y, Nishiwaki K, Quan YS, Kamiyama F, Oiso N, Kawada A, Kabashima K, Nakayama T. A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch containing ovalbumin. Biomed Pharmacother 2019; 109:1437-1444. [DOI: 10.1016/j.biopha.2018.10.194] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 10/31/2018] [Accepted: 10/31/2018] [Indexed: 01/06/2023] Open
|
10
|
Transcutaneous Immunization Using Nano-sized Drug Carriers. METHODS IN PHARMACOLOGY AND TOXICOLOGY 2016. [DOI: 10.1007/978-1-4939-3121-7_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
11
|
Recent insights into cutaneous immunization: How to vaccinate via the skin. Vaccine 2015; 33:4663-74. [PMID: 26006087 DOI: 10.1016/j.vaccine.2015.05.012] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Revised: 04/21/2015] [Accepted: 05/01/2015] [Indexed: 12/24/2022]
Abstract
Technologies and strategies for cutaneous vaccination have been evolving significantly during the past decades. Today, there is evidence for increased efficacy of cutaneously delivered vaccines allowing for dose reduction and providing a minimally invasive alternative to traditional vaccination. Considerable progress has been made within the field of well-established cutaneous vaccination strategies: Jet and powder injection technologies, microneedles, microporation technologies, electroporation, sonoporation, and also transdermal and transfollicular vaccine delivery. Due to recent advances, the use of cutaneous vaccination can be expanded from prophylactic vaccination for infectious diseases into therapeutic vaccination for both infectious and non-infectious chronic conditions. This review will provide an insight into immunological processes occurring in the skin and introduce the key innovations of cutaneous vaccination technologies.
Collapse
|
12
|
Hirakawa Y, Wakabayashi R, Naritomi A, Sakuragi M, Kamiya N, Goto M. Transcutaneous immunization against cancer using solid-in-oil nanodispersions. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00168d] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Solid-in-oil nanodispersions allowed cancer antigens to penetrate into skin to induce antigen-specific cancer immunity.
Collapse
Affiliation(s)
- Yuya Hirakawa
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| | - Rie Wakabayashi
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| | - Ayaka Naritomi
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| | - Masato Sakuragi
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| | - Noriho Kamiya
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| | - Masahiro Goto
- Department of Applied Chemistry
- Graduate School of Engineering
- Kyushu University
- Fukuoka 819-0395
- Japan
| |
Collapse
|
13
|
Okada N. [From basic principles to clinical applications on transcutaneous vaccine]. YAKUGAKU ZASSHI 2013; 133:1363-72. [PMID: 24292185 DOI: 10.1248/yakushi.13-00232-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The recent vigorous transnational migration of people and materials reflecting the development of transportation facilities, changes in social structure, and war disasters has increased the global spread of emerging and re-emerging infectious diseases. Vaccine, which is the major fundamental prophylaxis against infectious diseases, has greatly contributed to the maintenance and improvement of human health worldwide. However, the disadvantages of conventional injection systems hamper the speedy mass-vaccination and the global distribution of vaccines. Transcutaneous immunization systems, which are easy-to-use and low-invasive methods of vaccination, have the potential to overcome certain issues associated with injectable vaccinations. In this review, we provide an outline of recent trends in the development of techniques for the transcutaneous delivery of vaccine antigens. We also introduce basic and clinical research involving our transcutaneous immunization systems that incorporate self-dissolving microneedle patch.
Collapse
Affiliation(s)
- Naoki Okada
- Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
| |
Collapse
|
14
|
Kitaoka M, Imamura K, Hirakawa Y, Tahara Y, Kamiya N, Goto M. Needle-free immunization using a solid-in-oil nanodispersion enhanced by a skin-permeable oligoarginine peptide. Int J Pharm 2013. [DOI: 10.1016/j.ijpharm.2013.10.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|